INTRODUCTION
============

Physiologic tissue stiffness supports tissue-specific functions and is maintained in normal homeostatic conditions. In contrast, normal tissue stiffness becomes chronically increased in a variety of prevalent diseases, including fibrosis, sclerosis, and cancer, where it is increasingly pointed to as a major driving force of disease progression ([@B39]; [@B15]; [@B36]). In the context of pulmonary physiopathology, it is well known that lungs are soft and elastic organs, which enables the dramatic cyclic volume changes required for breathing. In contrast, normal pulmonary stiffness can be increased up to 30-fold in pulmonary fibrotic disorders concomitantly with a loss of normal pulmonary function and architecture ([@B47]; [@B34]). Of note, such tissue stiffening remains currently irreversible in idiophatic pulmonary fibrosis (IPF), which is a very aggressive disease characterized by the progressive and chronic replacement of normal pulmonary tissue by a stiff dysfunctional scar in the absence of any known cause ([@B43]; [@B34]). Intriguingly, unlike other pulmonary fibrotic disorders, IPF remains frequently lethal due to suboptimal therapeutic options, with a median survival of only ∼2--5 yr from time of diagnosis ([@B11]). Moreover, it is worth noting that IPF is a rare disease that affects ∼5 million patients worldwide, yet it has a prevalence of ∼1/5000 people that continues to rise ([@B43]). Accordingly, there is an urgent need in understanding the critical mechanobiological alterations that drive this devastating disease.

IPF progression is associated with the appearance of areas of active fibrosis referred to as fibroblast foci, which are rich in activated fibroblasts/myofibroblasts in the background of abundant fibrillar collagens ([@B75]; [@B61]; [@B43]). Myofibroblasts have been identified as major drivers of the progression of IPF and other fibrotic disorders ([@B34]; [@B36]). Likewise, myofibroblasts have been pointed to as major effector cells of tissue stiffening, since they combine the extracellular matrix (ECM)-synthesizing features of fibroblasts with the cytoskeletal characteristics of contractile smooth muscle cells. Indeed, the most common myofibroblast markers are the abundant extracellular deposition of fibrillar collagens and the intracellular overexpression of alpha-smooth muscle actin (α-SMA) ([@B43]; [@B35]). Although the processes underlying the aberrant accumulation of myofibroblasts in IPF remain poorly understood, it has been reported that transforming growth factor beta 1 (TGF-β1), which is the most potent fibroblast activator cytokine characterized to date, is frequently upregulated in fibrotic lung diseases ([@B75]; [@B61]; [@B43]). Moreover, studies using hydrogel-based culture substrata with tunable elasticity have revealed that TGF-β1 can induce α-SMA expression in stiff but not in soft substrata ([@B6]; [@B7]; [@B34]), thereby underscoring the prominent role of tissue stiffening in organ fibrosis.

In addition to α-SMA up-regulation, there is growing evidence that matrix stiffening alone can trigger the expression of collagens and other profibrotic factors independently of TGF-β1 in fibroblasts ([@B22]; [@B47]; [@B66]). Moreover, we recently showed that fibrosis-like extracellular rigidities alone can enhance the growth and survival of lung fibroblasts through β1 integrin and pFAK^Y397^ signaling ([@B57]). Conversely, it was reported that extracellular stiffening strongly suppressed fibroblast expression of cyclooxygenase-2 (COX-2) and synthesis of prostaglandin E2 (PGE2), which is an autocrine inhibitor of fibrogenesis ([@B47]). More recently it was described that gradients of matrix stiffness reminiscent of those occuring in fibrotic tissues can attract fibroblasts through durotaxis ([@B47]; [@B45]). Collectively, these previous in vitro studies support that tissue stiffening per se provides a strong profibrotic microenvironment. In agreement with this interpretation, a panel of basic, translational, and clinical IPF researchers gathered in 2014 by the National Heart, Lung and Blood Institute in the United States highlighted the need to "elucidate the mechanisms of matrix stiffening and cell responses to increased stiffness" as an important future direction in IPF research ([@B11]).

Given the prominent role of fibrogenic myofibroblasts in tissue stiffening and overall disease progression in IPF and other fibrotic disorders, there is increasing interest in defining their cellular source. It remains widely accepted that lung myofibroblasts arise from the proliferation and migration of resident fibroblasts. In addition, alveolar epithelial cells undergoing epithelial-to-mesenchymal transition (EMT) have been pointed to as potential contributors to the myofibroblast population ([@B75]; [@B61]; [@B34]). During EMT, epithelial cells undergo a dramatic phenotypic change that includes loosening cell--cell adhesions, down-regulating epithelial markers, up-regulating mesenchymal markers and pro-EMT transcription factors, and acquiring an elongated fibroblast-like morphology ([@B75]; [@B61]; [@B54]). In support of the EMT source of myofibroblasts, studies in vitro have revealed that EMT may be induced by TGF-β1 ([@B75]; [@B34]; [@B55]). Moreover, studies using in vivo models of pulmonary fibrosis support that a significant fraction of fibroblasts in fibrotic lesions may be epithelial derived ([@B41]; [@B78]; [@B42]; [@B19]). Likewise, cells coexpressing epithelial and mesenchymal markers have been reported in IPF biopsies ([@B76]; [@B41]; [@B79]). However, recent lineage tracing experiments have failed to unambiguously provide evidence of EMT in in vivo models of lung fibrosis ([@B59]; [@B36]), and technical concerns on previous EMT analyses of IPF biopsies have been raised ([@B59]). Similar controversial data have been reported in liver and kidney fibrosis ([@B38]; [@B9]; [@B29]; [@B36]). On the other hand, it should be mentioned that previous EMT studies have focused on the expression of epithelial and mesenchymal markers, whereas functional mechanical measurements have been largely absent. Accordingly, it remains unclear what the contribution of EMT is to the profibrotic stiff microenvironment and overall myofibroblast accumulation in IPF.

To shed light on these questions, we gathered a panel of EMT-competent lung epithelial cells and primary lung fibroblasts derived from either fibrosis-free donors (used as control cell models for resident fibroblasts) or IPF patients. To mimic a profibrotic microenvironment, we cultured cells on stiff culture substrata in the presence of exogenous TGF-β1 at concentrations capable of inducing both EMT and fibroblast activation. The phenotypic effects of the profibrotic microenvironment were analyzed in terms of morphology and expression of both EMT and myofibroblast markers. To assess the potential impact of pro-fibrotic stimuli on tissue mechanics, we analyzed cellular stiffness through nanoindentation measurements by atomic force microscopy (AFM) as well as the expression of fibrillar collagens.

Results
=======

TGF-β1 induces EMT in selected lung epithelial cell lines but fails to match the vimentin expression levels and morphological features of IPF-derived fibroblasts
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

Unlike fibroblasts, isolating and maintaining human lung epithelial cells remains rather challenging and poorly efficient ([@B62]; [@B81]). To overcome these limitations, we selected a panel of lung epithelial cell lines previously reported to express levels of epithelial and mesenchymal markers indicative of either a high (H441, PC9) or a moderate/low (A549, H1975) epithelial phenotype in basal conditions, which has been associated with poor or strong EMT competence, respectively ([@B68]; [@B80]; [@B84]; [@B40]). Although these four cell lines were originally derived from lung adenocarcinomas, they were selected because they are accepted models of either poor or strong EMT, and there is extensive evidence that major EMT hallmarks are shared between normal epithelial cells during development and selected transformed cells ([@B54]). Furthermore, the A549 cell line in particular is a widely used model of alveolar epithelial-like behavior in noncancer-oriented studies ([@B46]). To provide cells a profibrotic microenvironment, both epithelial cell lines and primary fibroblasts were cultured on tissue culture plastic for 24 h in culture medium containing 10% fetal bovine serum (FBS), thereby facilitating cell attachment to a rigid substrata ([@B56]). Next, cell cultures were washed, maintained in serum-free medium for 24 h to growth arrest and synchronize them, and, finally, stimulated for 3 d with serum-free medium (used as negative control) or 5 ng/ml TGF-β1, which is a master regulator of fibrosis in the lung and other organs ([@B75]; [@B61]). The latter conditions have been extensively reported to be sufficient to induce both fibroblast activation as well as EMT in A549 and other epithelial cell lines ([@B84]; [@B26]; [@B72]; [@B79]).

As expected, immunofluorescence analysis revealed that TGF-β1 stimulation induced EMT selectively in some of the epithelial cell lines ([Figure 1A](#F1){ref-type="fig"} and Supplemental Figure S1). Specifically, TGF-β1 increased the average expression of the mesenchymal marker vimentin by ∼50--100% in A549 and H1975 epithelial cells, whereas vimentin remained virtually unaltered in H441 and PC9 cell lines ([Figure 1B](#F1){ref-type="fig"}). Likewise, vimentin levels did not exhibit a significant fold increase in primary fibroblasts derived from different randomly selected control donors or IPF patients on TGF-β1 treatment ([Figure 1B](#F1){ref-type="fig"}), in agreement with previous observations ([@B32]). Conversely, TGF-β1 reduced the expression of the epithelial marker E-cadherin further in A549 and H1975, whereas H441 and PC9 cells retained high/moderate E-cadherin expression levels ([Figure 1, A and B](#F1){ref-type="fig"}, and Supplemental Figure S1). The down-regulation of E-cadherin by TGF-β1 in A549 cells was further confirmed by Western blotting (Supplemental Figure S1). In contrast, primary myofibroblasts were negative for E-cadherin. On the other hand, the absolute intensity values of vimentin fluorescence after TGF-β1 treatment shown in [Figure 1C](#F1){ref-type="fig"} were somewhat cell line (in epithelial cells) and patient (in fibroblasts) dependent, which may be associated with the particular genetic alterations of each cell line and the intrinsic patient variability, respectively, as well as with potential limitations in our image processing. Yet, despite the strong EMT phenotype in A549 and H1975 cells supported by the large fold induction of vimentin ([Figure 1B](#F1){ref-type="fig"}), their corresponding absolute vimentin levels in the presence of TGF-β1 were less than half of those found in IPF fibroblasts and control fibroblasts activated with TGF-β1 as shown in [Figure 1C](#F1){ref-type="fig"}. In addition, TGF-β1 treatment held the number of primary fibroblasts; likewise, it maintained or decreased the population of epithelial cells in a cell-line--dependent manner (Supplemental Figure S2), in agreement with previous results ([@B74]). These observations are consistent with the universal cytostatic effects and selective apoptotic function of TGF-β1 in epithelial cells ([@B63]). All these results on epithelial cells are consistent with previous observations ([@B80]; [@B79]) and support that TGF-β1 elicits a strong EMT phenotype in A549 and H1975 cells but not in H441 and PC9 cells. Accordingly, these cell lines were used as models of strong (A549, H1975) and weak (H441, PC9) EMT thereafter.

![Immunofluorescence analysis of epithelial (E-cadherin) and mesenchymal (vimentin) markers in EMT-competent lung epithelial cells and primary lung fibroblasts. (A) Representative immunofluorescence images of E-cadherin (left) and vimentin (right) in epithelial cell lines (H441, A549) and primary fibroblasts obtained from randomly selected control (fibrosis-free) or IPF patients (referred by the three-digit number following \# symbol) cultured for 3 d in the absence or presence of 5 ng/ml TGF-β1. Images were obtained with a ×20 objective (seven images/condition). Blue indicates DAPI staining here and thereafter. Scale bar here, 50 μm. Representative images from other epithelial cell lines (PC9, H1975) and patients are shown in Supplemental Figure S1. (B) Ratio of the average vimentin fluorescence intensity per cell obtained in the presence or absence of TGF-β1 in a panel of epithelial cell lines and primary fibroblasts from randomly selected control and IPF patients. Horizontal gray dashed line corresponds to no fold change (ratio = 1), whereas horizontal solid blue lines correspond to the average values for each cellular model (i.e., epithelial cells exhibiting weak or strong EMT, *n* = 2; and primary fibroblasts from control or IPF patients, *n* = 3). (C) Absolute average vimentin fluorescence intensity per cell obtained on stimulation with TGF-β1 in the same cell models shown in B. \**p* ≤ 0.05 with respect to 1 were determined by Student's *t* test (here and hereafter).](3741fig1){#F1}

A common feature of EMT is a morphological change in which epithelial cells exhibit an elongated fibroblast-like shape ([@B54]). To assess to what extent the shape of epithelial cell lines stimulated with TGF-β1 resembled that of actual lung fibroblasts, we conducted a morphometric analysis of phase contrast images of cells on a 3-d treatment with TGF-β1. In the absence of exogenous TGF-β1, both H441 and A549 cells exhibited cell--cell adhesions and a roundish shape with limited spreading, whereas all primary (nonactivated) fibroblasts exhibited the usual spindle shape and marked elongation ([Figure 2A](#F2){ref-type="fig"} and Supplemental Figure S3). On TGF-β1 stimulation, A549 cells scattered and exhibited a lower value of circularity (adimensional index constrained between 0 and 1, where 1 corresponds to a perfect circle) and a higher elongation (ratio between cell length and width) and spreading (cell projected area) than H441 cells ([Figure 2, B--D](#F2){ref-type="fig"}). The shape changes elicited by TGF-β1 in A549 are hallmarks of EMT ([@B54]; [@B55]) and were also observed in H1975 but not in PC9. Spreading analysis revealed a progressive increase in the average cell area in cells undergoing EMT (∼1500 μm^2^), control myofibroblasts (∼2500 μm^2^), and IPF myofibroblasts (∼3000 μm^2^) ([Figure 2D](#F2){ref-type="fig"}). The latter differences in spreading attained statistical significance between each EMT model compared with both sources of primary myofibroblasts but not between IPF and control myofibroblasts ([Figure 2D](#F2){ref-type="fig"}).

![Morphometric analysis of EMT-competent lung epithelial cells and primary lung fibroblasts stimulated with the profibrotic cytokine TGF-β1 for 3 d. (A) Representative phase contrast images of epithelial cells (H441, A549) and primary fibroblasts obtained from randomly selected control or IPF patients in the absence or presence of TGF-β1. Images were obtained with a ×20 objective (two to three images/condition). Scale bar, 50 μm. Representative images from other epithelial cell lines (PC9, H1975) and patients are shown in Supplemental Figure S3. (B--D) Average cell values of the circularity (B), elongation (C), and spreading (D) assessed on stimulation with TGF-β1 in epithelial cells undergoing weak or strong EMT and in primary fibroblasts from control or IPF patients. On average, 30 cells were analyzed per experimental condition. \**p* ≤ 0.05, \*\**p* ≤ 0.01, and \*\*\**p* ≤ 0.005 with respect to IPF fibroblasts; ^\#^*p* ≤ 0.05, ^\#\#^*p* ≤ 0.01, and ^\#\#\#^*p* ≤ 0.005 with respect to control fibroblasts. All comparisons were determined by Student's *t* test.](3741fig2){#F2}

Likewise, all morphological parameters were statistically different between weak and strong EMT models (*p* \< 0.05, Student's *t* test) but not between control and IPF fibroblasts. However, to address our main goal (i.e., compare different EMT models with fibroblasts), and for the sake of simplicity, we reduced two-group comparisons to those between different EMT models and fibroblasts only. Of note, the morphological differences between cells undergoing EMT and primary fibroblasts stimulated with TGF-β1 were even more dramatic and statistically significant in terms of elongation and circularity than of spreading. Collectively, these results indicate that TGF-β1 induces a mesenchymal-like phenotype in EMT-competent cells but fails to match the vimentin expression and morphological features of activated primary fibroblasts.

TGF-β1 induces a robust assembly of α-SMA into stress fibers in primary fibroblasts but not in cells undergoing EMT
-------------------------------------------------------------------------------------------------------------------

The primary marker of the myofibroblast phenotype in vitro is the expression of α-SMA and its assembly into a cytoskeleton rich in stress fibers ([@B69]). In addition, some authors have described an intermediate phenotype between a nonactivated fibroblast and a myofibroblast characterized by the prominent presence of stress fibers containing little or no α-SMA and have referred to it as proto-myofibroblast ([@B69]; [@B34]). To visualize simultaneously both the actin cytoskeleton and α-SMA, we immunostained cells cultured as in the previous experiments for both F-actin and α-SMA, as shown in [Figure 3](#F3){ref-type="fig"} and Supplemental Figure S4, and performed two complementary colocalization analyses with ImageJ ([@B1]). First, we computed the Manders colocalization coefficient M(α-SMA), which measures the fraction of α-SMA co-occurring with F-actin staining ([@B50]). This coefficient is constraint between 0 (absence) and 1 (complete colocalization) and is considered the most biologically relevant quantitative assessment of colocalization ([@B21]). As shown in [Figure 4A](#F4){ref-type="fig"}, the average M(α-SMA) values on TGF-β1 stimulation were similarly very high in both IPF fibroblasts and control fibroblasts (\>0.95) compared with epithelial cells exhibiting either strong (∼0.8) or weak (∼0.7) EMT. The M(α-SMA) values of each EMT model (but not in control fibroblasts) were statistically different than those of IPF fibroblasts. These results reveal that EMT failed to match the colocalization found in activated primary fibroblasts.

![Visualization of the actin cytoskeleton, α-SMA, and their colocalization on stimulation with TGF-β1 for 3 d. Selected regions from representative immunofluorescence images of F-actin (left), α-SMA (middle), and their corresponding colocalization (right) in epithelial cells (H441, A549) and primary fibroblasts obtained from randomly selected control or IPF patients cultured in the absence or presence of 5 ng/ml TGF-β1. The colocalization of F-actin and α-SMA was labeled in white. Images were obtained with a ×20 objective (seven images/condition). Scale bar, 50 μm. Full images as well as additional representative images from other epithelial cell lines (PC9, H1975) and patients are shown in Supplemental Figure S4.](3741fig3){#F3}

![Assembly of α-SMA into stress fibers in EMT-competent lung epithelial cells and primary lung fibroblasts on stimulation with TGF-β1 for 3 d. (A) Quantitative colocalization analysis of the images in [Figure 3](#F3){ref-type="fig"} through the Manders colocalization coefficient M(α-SMA), which corresponds to the fraction (between 0 and 1) of α-SMA co-occurring with F-actin. (B) Colocalization analysis of the images in [Figure 3](#F3){ref-type="fig"} in terms of the percentage of cells stimulated with TGF-β1 that exhibited at least three straight and continuous white lines (green bars) or three straight and discontinuous (but not speckled) white lines (red bars), which were interpreted as apparent (well-differentiated) myofibroblasts or proto-myofibroblasts, respectively. (C) Absolute average F-actin fluorescence intensity per cell obtained on stimulation with TGF-β1 in epithelial cells undergoing weak or strong EMT and in primary fibroblasts from either control or IPF patients. Statistical analysis as in [Figure 2](#F2){ref-type="fig"}.](3741fig4){#F4}

Since M(α-SMA) values capture global rather than specific colocalization of α-SMA into stress fibers, we conducted a second (qualitative) visual colocalization analysis with ImageJ based on highlighting in white overlapping F-actin and α-SMA stainings as shown in [Figure 3](#F3){ref-type="fig"} and Supplemental Figure S4. This visual analysis revealed abundant white straight lines suggestive of α-SMA aligned into actin stress fibers in both control and IPF fibroblasts on TGF-β1 stimulation, whereas such white straight lines were much less abundant or largely absent in epithelial cells exhibiting strong or weak EMT, respectively. In an attempt to relate these colocalization images with the appearance of the myofibroblast phenotype, those cells exhibiting at least three straight and continous white (colocalization) straight lines were taken as apparent well-differentiated myofibroblasts, whereas cells that did not fulfill the latter criteria but exhibited at least three straight but discontinuous white lines (not speckled/noisy looking) were counted as proto-myofibroblast--like cells. The latter colocalization analysis revealed a progressive increase in the percentage of apparent proto-myofibroblasts in cells undergoing EMT (∼5%), control fibroblasts (∼15%), and IPF fibroblasts (∼20%) on 3-d stimulation with TGF-β1. In contrast, apparent well-differentiated myofibroblasts were observed in both control and IPF fibroblasts to a similar extent (∼40%), but they were largely absent in EMT models ([Figure 4B](#F4){ref-type="fig"}). Adding the percentages of apparent proto-myofibroblasts and well-differentiated myofibroblasts elicited an average ∼60% value in both control and IPF fibroblasts, which is consistent with the percentages of α-SMA positive cells reported in primary lung fibroblasts obtained from the same type of IPF and control (fibrosis-free) patients elsewhere ([@B26]).

Given the importance of F-actin in cell mechanics ([@B5]), we also analyzed quantitatively F-actin fluorescence stainings. Unlike vimentin stainings, we observed a similar average F-actin intensity in all EMT models (i.e., weak and strong) in response to 5 ng/ml TGF-β1 that was approximately fourfold lower than the F-actin intensity obtained in both control and IPF myofibroblasts ([Figure 4C](#F4){ref-type="fig"}). Collectively these observations reveal that EMT-competent lung cells do not exhibit standard cytoskeletal markers indicative of well differentiated myofibroblasts when stimulated with TGF-β1 in vitro.

Potential relative contribution of epithelial cells and fibroblasts to the stiff microenvironment in IPF
--------------------------------------------------------------------------------------------------------

The stiff microenvironment that characterizes IPF and other fibrotic disorders has been largely associated with the enhanced contractile properties of myofibroblasts and their excessive deposition of fibrillar collagens ([@B43]; [@B34]; [@B36]). To assess the relative contribution of cells undergoing EMT to such stiff microenvironment in the context of IPF at the cellular level, we first measured cell stiffening in response to TGF-β1 by nanoindentation measurements with AFM, which enables computing the local Young's modulus (*E*) of single cells ([@B3]). *E* is a standard physical parameter that describes the resistance of a sample to the deformation imposed by a low/moderate external loading force, and is widely used to characterize the mechanical properties of cells and other biological samples ([@B15]; [@B31]). In addition, we previously reported that *E* measurements are good indicators of cellular contractility ([@B58]). During each nanonindentation measurement, a cantilever force sensor provided with a micrometer sized pyramidal blunted tip---exhibiting a radius of curvature at the apex of ∼20 nm---was brought into contact with the cell surface ([Figure 5A](#F5){ref-type="fig"}) and used to apply an increasing loading force up to ∼1 nN while monitoring cell resistance to deformation. These conditions elicited a maximum tip-cell contact area (∼0.1--0.2 μm^2^), which is approximately three orders of magnitude lower than cell spreading data ([Figure 2D](#F2){ref-type="fig"}), thereby probing the local mechanical properties of the cell. Caution was taken to perform nanoindentation measurements at the perinuclear region and at low/moderate relative indentations to probe the mechanics of the cytoskeleton while minimizing contributions of the nucleus and the underlying tissue culture plastic ([@B58]; [@B31]). *E* data for each cell line and patient are shown in Supplemental Figure S5. To assess cell stiffening, we computed the ratio of *E* measured in the presence or absence of TGF-β1. As shown in [Figure 5B](#F5){ref-type="fig"}, TGF-β1 stiffened all epithelial cell models in a cell-line--dependent manner but PC9, which may be associated with the particular genetic alterations of this cell line (see the Supplemental Material for an extended discussion). However, the largest cell stiffening elicited by TGF-β1 was consistenly observed in IPF fibroblasts (∼3-fold on average), whereas TGF-β1 induced only a modest cell stiffening in control fibroblasts (∼1.5-fold) ([Figure 5B](#F5){ref-type="fig"}).

![Nanoindentation elasticity measurements of single cells carried out with AFM on lung epithelial cells and primary lung fibroblasts. (A) Representative phase contrast image of an AFM force sensor (cantilever) on top of a single lung epithelial cell (A549). AFM force sensors were used to indent locally the cell surface and assess the corresponding opposing force to compute the Young's modulus (*E*) as described in *Material and Methods*, using three technical replicates. (B) Ratio of the average *E* values obtained on single cells cultured in the presence or absence of TGF-β1 in a panel of epithelial cell lines (*n* = 4) and primary fibroblasts from randomly selected control (*n* = 5) and IPF (*n* = 5) patients. On average 10 cells were measured per experimental condition (two independent experiments). Horizontal gray dashed line corresponds to no fold change (ratio = 1), whereas horizontal solid blue lines correspond to the average values for each cellular model (i.e., epithelial cells exhibiting weak or strong EMT, and primary fibroblasts from control or IPF patients) as in [Figure 1B](#F1){ref-type="fig"}. The *E* data for each cell line and patient are shown in Supplemental Figure S5. Statistical analysis as in [Figure 1B](#F1){ref-type="fig"}. (C) *E* values obtained on single cells on TGF-β1 stimulation from each cellular model. Red horizontal lines correspond to the average *E* values for each model as in [Figure 1C](#F1){ref-type="fig"}. The semi-transparent orange horizontal band corresponds to the *E* values assessed on normal pulmonary tissue elsewhere (see the main text for references) and was added to illustrate the aberrant mechanical behavior of IPF fibroblasts. Statistical analysis as in [Figure 2](#F2){ref-type="fig"}.](3741fig5){#F5}

To better compare the potential contribution of EMT cells and myofibroblasts to tissue stiffness, we plotted the absolute *E* values of single cells recorded after 3 d of TGF-β1 stimulation concomitantly with a horizontal band spanning the physiologic range of *E* data from pulmonary tissue (∼2--10 kPa) reported elsewhere ([@B22]; [@B47]; [@B13]) in [Figure 5C](#F5){ref-type="fig"}. Although we observed a progressive increase in *E* in cells undergoing EMT (∼5 kPa), control myofibroblasts (∼8 kPa) and IPF myofibroblasts (∼13 kPa), their average *E* values were beyond the physiologic range in IPF myofibroblasts only ([Figure 5C](#F5){ref-type="fig"}). Interestingly, the difference in *E* values observed in control and IPF myofibroblasts was statistically significant, supporting our initial observation of larger cell stiffening in myofibroblasts from IPF patients compared with those from control donors ([Figure 5B](#F5){ref-type="fig"}). Likewise, *E* values of epithelial cells undergoing EMT were also different from *E* values obtained in either control or IPF fibroblasts with statistical significance. In addition we noticed that the differences in the average *E* values of cells undergoing EMT and primary myofibroblasts were much lower than the differences between other parameters examined in this study that had been previously pointed to as regulators of cell stiffness, including spreading ([Figure 2D](#F2){ref-type="fig"}), F-actin ([Figure 4C](#F4){ref-type="fig"}), and apparent myofibroblast enrichment ([Figure 4, A and B](#F4){ref-type="fig"}) ([@B58]; [@B34]). These observations suggest that the mechanical differences between epithelial cells undergoing EMT and myofibroblasts are due to other unidentified factors.

We next analyzed the expression of type I and type III collagens, which are the most abundant fibrillar collagens that are also frequently used as myofibroblast and EMT markers, respectively ([@B24]; [@B35]). For this purpose, we assessed the mRNA levels of *COL1A1* and *COL3A1* genes by quantitative reverse transcription PCR (qRT-PCR) in cells stimulated with TGF-β1 for 3 d as in the previous experiments. In agreement with cell mechanical data, the expression of both *COL1A1* and *COL3A1* was moderately higher (35 and 25%, respectively) in myofibroblasts from IPF patients compared with those from control donors, and this difference attained statistical significance ([Figure 6, A and B](#F6){ref-type="fig"}). In contrast, the expression of these genes in epithelial cells undergoing EMT was 3 orders of magnitude lower than in myofibroblasts. Interestingly, the expression of *COL3A1* (but not *COL1A1*) in epithelial cells exhibiting a weak EMT was 3 orders of magnitude lower than those exhibiting strong EMT, providing additional support that *COL3A1* is a suitable EMT marker ([@B24]). To validate the differences in the mRNA levels of fibrillar collagens between myofibroblasts from IPF and control patients at the protein level, we assessed the total amount of secreted collagen (types I--V) in the culture medium of primary fibroblasts stimulated with TGF-β1 for 3 d using the Sircol collagen assay as shown in [Figure 6C](#F6){ref-type="fig"}. Total secreted collagen was ∼25% higher in myofibroblasts from IPF compared with control patients, which is very close to the ∼35% and ∼25% increases in *COL1A1* and *COL3A1* mRNA expression in the former cells, respectively.

![Expression of fibrillar collagens in EMT-competent lung epithelial cells and primary lung fibroblasts on stimulation with TGF-β1 for 3 d. (A, B) mRNA levels of *COL1A1* (A) and *COL3A1* (B) assessed by qRT-PCR using three technical replicates. *POLR2A* was used as endogenous gene. (C) Total secreted collagens of primary myofibroblasts assessed with the Sircol assay. Statistical analysis as in [Figure 2](#F2){ref-type="fig"}. Note the vertical log scale in A and B.](3741fig6){#F6}

Combining the mechanical and collagen expression data supports that myofibroblasts are the larger contributors to the stiff microenvironment in terms of both cell stiffness and expression of fibrillar collagens. Moreover, to the best of our knowledge, our results show for the first time that the contribution of epithelial cells undergoing EMT to the stiff microenvironment may be relevant in terms of cell stiffness but not of expression of fibrillar collagens. In addition, our measurements reveal that myofibroblasts derived from IPF patients exhibit aberrant mechanobiology responses to TGF-β1 in terms of both cell stiffness and expression of fibrillar collagens, which may be a critical contributor of the profibrotic tissue stiffening in IPF.

Once elucidated that EMT fails to induce a myofibroblast-like phenotype in our cell models in vitro, we wondered whether EMT may induce bona fide traits of nonactivated fibroblasts. For this purpose, we compared the average values of all the parameters examined throughout this work in both EMT-competent cells stimulated with TGF-β1 and in (nonactivated) fibroblasts from control donors cultured in the absence of TGF-β1. As shown in [Figure 7](#F7){ref-type="fig"}, cells undergoing EMT could be distinguished from nonactivated primary fibroblasts in all parameters but spreading, exhibiting the largest differences in terms of vimentin ([Figure 7A](#F7){ref-type="fig"}), morphology (elongation, circularity) ([Figure 7, E and F](#F7){ref-type="fig"}), and expression of both *COL1A1* and *COL3A1* ([Figure 7, H and I](#F7){ref-type="fig"}).

![Comprehensive comparison of the phenotype of lung cells undergoing EMT on stimulation with TGF-β1 and that of nonactivated primary fibroblasts from control donors cultured in the absence of TGF-β1 in terms of vimentin (A), F-actin (B), % of apparent proto-myofibroblasts/myofibroblasts (C), spreading (D), circularity (E), elongation (F), stiffness (G), and expression of *COL1A1* (H) and *COL3A1* (I). Statistical analysis as in [Figure 2](#F2){ref-type="fig"}.](3741fig7){#F7}

FAK^Y397^ activity is enhanced in IPF fibroblasts compared with control fibroblasts stimulated with TGF-β1, which may underlie the larger stiffness and collagen expression of the former
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Prompted by the enhanced stiffness and expression of fibrillar collagens of IPF fibroblasts compared with control fibroblasts on TGF-β1 stimulation, we began to examine potential underlying mechanisms. Focal adhesion kinase (FAK) is an important regulator of the bidirectional cell-ECM mechanical interactions in fibroblasts and other cell types through its phosphorylation at Y397, which is also upregulated by TGF-β1 ([@B67]; [@B52]; [@B36]). Interestingly, previous in vivo studies revealed that FAK^Y397^ activity is enhanced within fibroblast foci in IPF patients ([@B16]; [@B44]; [@B20]), and its forced down-regulation protected against bleomycin-induced lung fibrosis in mice ([@B44]; [@B86]). To examine FAK^Y397^ activity in our in vitro models, we first identified a suitable timing on TGF-β1 stimulation by conducting a time-course experiment in control fibroblasts ([Figure 8A](#F8){ref-type="fig"}). Western blot analysis revealed a peak in FAK^Y397^ at ∼6 h, which is in agreement with previous studies ([@B67]) and was used thereafter. Of note, FAK^Y397^ activity was increased approximately twofold in IPF fibroblasts compared with control fibroblasts following TGF-β1 treatment ([Figure 8B](#F8){ref-type="fig"}). To assess whether enhanced FAK activity is sufficient to increase fibroblast stiffness and/or expression of fibrillar collagens, we took advantage of a well-established FAK cell model based on mouse embryonic fibroblasts that are either wild type (FAK^+/+^) or FAK null (FAK^--/--^) ([@B44]). As expected, TGF-β1 increased FAK^Y397^ activity in FAK^+/+^ fibroblasts, whereas the expression of both total FAK and FAK^Y397^ were largely absent in FAK^--/--^ fibroblasts ([Figure 8C](#F8){ref-type="fig"}). Likewise, AFM analysis reported ∼60% larger average *E* values in FAK^+/+^ compared with FAK^--/--^ fibroblasts ([Figure 8D](#F8){ref-type="fig"}), which was associated with a larger percentage of α-SMA colocalized with F-actin in the former as revealed by immunofluorescence ([Figure 8E](#F8){ref-type="fig"}). In agreement with AFM data, qRT-PCR measurements showed a strikingly higher expression of both *Col1a1* and *Col3a1* mRNA levels in FAK^+/+^ compared with FAK^--/--^ fibroblasts on TGF-β1 stimulation ([Figure 8, F and G](#F8){ref-type="fig"}). Taken together, and to the best of our knowledge, these observations report for the first time a larger FAK^Y397^ activity in TGF-β1-activated fibroblasts derived from IPF patients compared with control patients, and strongly support that such FAK^Y397^ hyperactivation may be a driving mechanism underlying the aberrant mechanobiology of IPF fibroblasts, at least in terms of cell stiffness and expression of fibrillar collagens.

![Analysis of FAK^Y397^ activity in primary fibroblasts on TGF-β1 stimulation, and effect of loss of FAK activity in the stiffness, cytoskeletal organization, and collagen expression of fibroblasts. (A) Representative Western blot showing the time-course expression of FAK^Y397^, total FAK, and β-actin in primary control fibroblasts stimulated with TGF-β1. (B) Representative Western blot showing FAK^pY397^ and total FAK of control fibroblasts and IPF fibroblasts stimulated with TGF-β1 for 6 h; right: corresponding densitometry analysis of FAK^pY397^/FAK in control (*n* = 4) and IPF fibroblasts (*n* = 4). (C) Representative Western blot showing FAK^pY397^, total FAK and α-tubulin of FAK wild-type (FAK^+/+^), or FAK null (FAK^--/--^) mouse embryonic fibroblasts stimulated with TGF-β1 for 6 h; right: corresponding densitometry analysis of FAK^pY397^/α-tubulin (*n* = 3). (D) *E* of FAK^+/+^ and FAK^--/--^ fibroblasts stimulated with TGF-β1 for 3 d assessed by AFM as in [Figure 5](#F5){ref-type="fig"}. (E) Selected regions from representative immunofluorescence images of F-actin (left), α-SMA (middle), and their corresponding colocalization (right) of FAK^+/+^ and FAK^--/--^ fibroblasts stimulated with TGF-β1 for 3 d. Images were obtained as in [Figure 3](#F3){ref-type="fig"}. Scale bar, 50 μm. (F, G) mRNA levels of *Col1a1* (F) and *Col3a1* (G) of FAK^+/+^ and FAK^--/--^ fibroblasts stimulated with TGF-β1 for 3 d assessed as in [Figure 6](#F6){ref-type="fig"}. Statistical analysis as in [Figure 2](#F2){ref-type="fig"} (*n* = 2, unless otherwise indicated).](3741fig8){#F8}

DISCUSSION
==========

It is increasingly acknowledged that the chronic stiffening of the tissue microenvironment observed in IPF and other fibrotic disorders provides profibrotic cues that are essential for the progression of organ fibrosis ([@B34]; [@B36]). Myofibroblasts are pointed to as critical effector cells in both tissue stiffening and fibrosis progression in the lung and other organs ([@B43]; [@B34]; [@B36]). Yet it remains controversial what the contribution of epithelial cells undergoing EMT is to tissue stiffening and overall myofibroblast population ([@B9]; [@B55]). By examining a panel of commonly used lung EMT models, we found evidence supporting that lung cells undergoing EMT may contribute to the profibrotic stiff microenvironment through their enhanced endogenous stiffness but not through their expression of fibrillar collagens. In addition, we found that EMT renders a phenotype that is clearly different from that of myofibroblasts derived from IPF patients in terms of mechanics, collagen expression, morphology, and cytoskeletal organization. Indeed, cells undergoing EMT could be easily distinguished even from nonactivated fibroblasts, thereby challenging the ability of EMT to provide myofibroblast precursors further, unlike previously suspected ([@B41]; [@B75]; [@B19]; [@B79]). Conversely, the responses of fibroblasts derived from control (fibrosis-free) donors---which were used to model resident fibroblasts---to the profibrotic cytokine TGF-β1 were similar to those of myofibroblasts derived from IPF patients in all the parameters examined. Accordingly, our data support that myofibroblasts in IPF are directly populated largely from resident fibroblasts ([@B59]; [@B29]). In contrast, EMT may contribute indirectly to the myofibroblast population in IPF by perturbing normal parenchymal architecture (through loss of cell--cell adhesions required for alveolar integrity) and by providing profibrotic cytokines, in agreement with previous observations in mouse models of pulmonary fibrosis or renal fibrosis on induction of partial EMT ([@B78]; [@B42]; [@B33]).

Previous AFM mechanical measurements in the context of pulmonary fibrosis have been limited to whole and decellularized tissue sections ([@B47]; [@B51]; [@B5]), whereas no studies have been conducted on IPF fibroblasts. Likewise, most previous EMT studies have focused on the expression of epithelial and mesenchymal markers, whereas studies examining the corresponding mechanical alterations had been scarce ([@B54]; [@B14]; [@B9]). Remarkably, our AFM measurements revealed that the average cell stiffness (*E*) of IPF myofibroblasts was beyond the physiologic range of pulmonary tissue stiffness, whereas that of myofibroblasts from control donors was not, underscoring the aberrant mechanical behavior of IPF myofibroblasts. Moreover, we found that a panel of lung cells undergoing EMT stiffened on average up to fourfold in response to TGF-β1, although their average *E* was ∼50% lower than that of control fibroblasts. Such a range of cell stiffening is in agreement with the twofold increase in *E* of A549 cells measured by AFM on treatment with 5 ng/ml TGF-β1 for 48 h elsewhere ([@B14]) and with the fivefold stiffening reported in mouse mammary epithelial cells stimulated with 10 ng/ml TGF-β1 for 48 h ([@B60]). To the best of our knowledge, our observations provide the first direct evidence of the mechanical diffences between cells undergoing EMT and myofibroblasts probed by AFM, and support that the contribution of the former to the tissue stiffening in IPF cannot be neglected, even though it is lower than that of myofibroblasts.

Most of the few previous attempts to examine the responses of normal lung epithelial cells to TGF-β have used type II alveolar epithelial cells (AECs) derived from rodents ([@B83]; [@B76]; [@B10]; [@B85]). These studies have consistently reported anti-proliferative effects of TGF-β1, which were also observed in the four epithelial cell lines used here. Likewise, a previous study of EMT induction by TGF-β1 on rat AECs reported common EMT hallmarks (i.e., down-regulation of epithelial markers, a fibroblast-like morphology, and an up-regulation of mesenchymal markers, including vimentin, type I collagen, and α-SMA) ([@B76]) that are reminiscent of our observed EMT induction elicited by TGF-β1 in selected cell lines (A549 and H1975). The latter similarity is unsurprising considering that EMT hallmarks have been reported in both normal epithelial cells during development and in pathologic conditions including organ fibrosis and cancer ([@B54]). Thus, even though the molecular underpinnings underlying TGF-β1 responses may be altered during malignant transformation (particularly in PC9 cells), the consistently similar responses to TGF-β1 in terms of cytostasis, stiffening, and expression of EMT markers compared with normal rodent epithelial cells reported elsewhere support that the former were a reasonable experimental model to address the aims of this study.

The enhanced cellular stiffening of both IPF myofibroblasts and selected epithelial cells undergoing EMT may have important profibrotic consequences. First, it may increase directly tissue rigidity through the expected enhanced traction forces and ECM adhesion strength of both cell types ([@B58]; [@B2]; [@B72]), which is in agreement with the critical mechanical roles of fibroblasts during the final contraction of a wound closure ([@B65]) and on the mechanical strength of fibroblast-populated three-dimensional collagen gels ([@B73]; [@B28]). Moreover, cell stiffening may contribute indirectly to tissue stiffening by increasing the activation of extracellular TGF-β1, for there is growing evidence that such activation requires intracellular tension ([@B34]; [@B55]). Since matrix stiffness and TGF-β1 can cooperate to activate fibroblasts and promote EMT, all these observations support that cell stiffening contributes to a vicious cycle in which matrix stiffening activates fibroblasts and promotes EMT, which in turn increase tissue stiffness further, thereby amplifying fibrosis ([@B47]; [@B36]).

We previously showed that increasing the concentration of type I collagen or collagen cross-linking in acellular hydrogels was sufficient to effectively increase gel stiffness as measured by AFM ([@B4]; [@B71]; [@B30]). Based on the latter evidence and on the reported abundant deposition of fibrillar collagens and collagen crosslinkers concomitantly with tissue stiffening in organ fibrosis ([@B8]; [@B47]; [@B43]; [@B34]; [@B36]), it is conceivable that the excessive and sustained expression of fibrillar collagens in fibrogenic myofibroblasts (but not in epithelial cells undergoing EMT) may directly contribute to the tissue stiffening in IPF. In addition, such excessive collagen expression may contribute to IPF progression through other processes, including disrupting normal alveolar architecture ([@B82]), providing a profibrotic hypoxic microenvironment by hindering oxygen diffusion ([@B54]; [@B18]; [@B36]) and even hindering the diffusion of molecular therapeutics ([@B23]; [@B27]). Conversely, all these observations strongly suggest that restoring normal collagen homeostasis may be a useful therapeutic strategy in organ fibrosis. In support of this hypothesis, we and others have reported that nintedanib---a recently approved drug to treat IPF---markedly reduces collagen expression by fibroblasts in vitro and in vivo ([@B37]; [@B77]; [@B25]).

Remarkably, our in vitro analysis revealed modest yet significantly larger responses to TGF-β1 in fibroblasts derived from IPF patients compared with control donors in terms of both cell stiffness and expression of fibrillar collagens. Likewise, TGF-β1 elicited larger FAK^Y397^ activity in IPF fibroblasts compared with control fibroblasts, thereby expanding previous histologic observations of enhanced FAK^Y397^ expression within fibroblast foci in IPF samples ([@B16]; [@B44]; [@B20]). On the other hand, we found that FAK depletion in fibroblasts was sufficient to markedly reduce both the stiffness and expression of fibrillar collagens in response to TGF-β1, concomitantly with a decrease in α-SMA colocalized with actin stress fibers. In agreement with our findings, a previous study on the FAK-related nonkinase protein FRNK, which is an independently expressed protein that negatively regulates FAK, reported its down-regulation in IPF samples; moreover, genetic down-regulation of FRNK in mouse fibroblasts was sufficient to increase FAK^Y397^ concomitantly with collagen expression, contractility, and α-SMA in response to TGF-β1 ([@B20]). Unlike cell stiffness and collagen expression, we could not detect statistically significant differences between IPF fibroblasts and control fibroblasts in terms of F-actin content and its colocalization with α-SMA. The latter negative observations may reflect either lack of sufficient resolution in our immunofluorescence quantitative approaches or that the aberrant mechanical features of IPF myofibroblasts are due to other cytoskeletal associated proteins. Taken together, these novel observations support that FAK^Y397^ hyperactivation in IPF fibroblasts may be a driving mechanism of the aberrant mechanobiology of these cells. Moreover, they support that targeting FAK^Y397^ could be a suitable therapeutic approach aiming to restore normal fibroblast mechanobiology in IPF. In support of these interpretations, both pharmacologic and genetic inhibition of FAK activity protected against bleomycin-induced lung fibrosis in mice ([@B44]; [@B86]).

In summary, our study sheds light on the controversial contribution of EMT to the increased myofibroblast population in IPF. In addition, our work provides evidence supporting the direct pathologic contribution of IPF myofibroblasts to the stiff microenvironment in IPF through their own aberrant stiffness and excessive expression of fibrillar collagens, and reveals that such aberrant mechanobiology is associated with FAK^Y397^ hyperactivation. Moreover, our results support that EMT may contribute to tissue stiffening by increasing epithelial cell stiffness, although to a lesser extent than myofibroblasts, but not through collagen deposition. Our results underscore also the remarkable potential of TGF-β1 to increase tissue stiffness through its direct impact on cell stiffness and collagen expression in the context of an already stiff microenvironment. These novel insights may help in designing future therapeutic studies aiming to restore normal mechanobiology in IPF ([@B36]).

MATERIAL AND METHODS
====================

Isolation of adult human lung fibroblasts
-----------------------------------------

Primary fibroblasts were isolated in sterile conditions by outgrowth of tissue explants from pulmonary tissue as described elsewhere ([@B26]) and frozen stored in liquid nitrogen at passages 2 and 3 until use. This procedure was approved by the Ethics Committees of the Hospital Clínic de Barcelona and the Universitat de Barcelona. Histologically normal parenchymal tissue was obtained from patients undergoing surgical pleurodesis to treat recurrent spontaneous pneumothorax (*n* = 9). IPF tissue was obtained from lung biopsies of patients exhibiting the histopathological pattern of usual interstitial pneumonia (*n* = 8). Patients gave written informed consent.

Cell culture and treatments
---------------------------

Before experiments, fibroblasts were fast thawed and grown in fibroblast culture media containing DMEM supplemented with 10% FBS (FBS Gold, PAA Laboratories), 100 IU/ml penicillin, 100 mg/ml streptomycin (Invitrogen), and 2 mg/ml amphotericin B (Sigma). All fibroblasts were used up to five to six passages to prevent replicative senescence and guarantee their phenotypic stability ([@B17]; [@B49]). H441 and A549 lung adenocarcinoma cell lines were obtained from the American Type Culture Collection (ATCC). PC9 and H1975 lung adenocarcinoma cell lines were kindly provided by Miquel Tarón (USP Dexeus University Institute, Barcelona, Spain), and their identity was confirmed in terms of accepted *EGFR* mutations ([@B12]; [@B70]) as described elsewhere ([@B53]; [@B64]). Epithelial cells were maintained in culture medium consisting of HEPES (Sigma)-buffered RPMI 1640 medium supplemented with 10% FBS, 1 mM [l]{.smallcaps}-glutamine (Invitrogen), and the same antibiotics as in fibroblasts. Mouse embryonic fibroblasts from wild-type (FAK^+/+^) or FAK-deficient (FAK^--/--^) mice (ATCC) were cultured in DMEM as previously described ([@B44]). All cultures were kept in a 5% CO~2~ humidified incubator at 37°C. For experiments on tissue culture plastic or glass substrata, cells were seeded in the corresponding culture media until they reached ∼80% confluency (∼1 to 2 d), washed three times in phosphate-buffered saline (PBS), growth arrested in serum-free culture media (SFM) for 24 h, and treated for 3 d with SFM alone (used as control) or supplemented with 5 ng/ml human TGF-β1 (R&D Systems).

Bright-field optical microscopy
-------------------------------

To assess major morphological features, cells were examined under an inverted optical microscope (Eclipse TE2000; Nikon) placed on a vibration isolation table (Isostation; Newport), using a ×20 objective and phase contrast optics. Phase contrast images were acquired with a cooled charge-coupled device (CCD) camera (Orca AG; Hamamatsu Photonics). Cell spreading (*A*), elongation, perimeter (*P*), and circularity (*C*, computed as *C* = 4·π·*A*/*P*^2^) were assessed by manually tracing the boundary of single cells by ImageJ ([@B1]) as reported elsewhere ([@B58]; [@B49]).

Fluorescence microscopy and image quantification
------------------------------------------------

Cells were cultured on four-well chamber slides (BD Falcon) to analyze the expression of EMT and myofibroblast markers by immunofluorescence. Slides were washed with PBS, fixed with cold 4% paraformaldehyde (Sigma) for 15 min, permeabilized with 0.5% Triton X-100 for 30 min, and blocked with 1% bovine serum albumin (BSA) in PBS for 1 h. Chamber slides were incubated for 1 h at 37°C with primary antibodies against either α-SMA (1:500), vimentin (1:100) (Invitrogen), or E-cadherin (1:100) (BD Biosciences). To detect each primary antibody, chamber slides were washed with PBS and incubated with a suitable fluorescent secondary antibody for 1 h at 37°C. F-actin was detected by incubating with tetramethylrhodamine (TRITC)-phalloidin (Sigma) for 1 h. Nuclei were counterstained with DAPI (4′,6-diamidino-2-phenylindole; 1:10,000; Sigma). Slides were mounted with Prolong gold antifade reagent (Invitrogen). To quantify the fluorescence signal from a specifically labeled protein, slides were mounted on the motorized stage of the Eclipse TE2000 microscope (Nikon), and images were captured at seven randomized nonoverlapping locations with a ×20 objective and a cooled CCD camera (Orca AG) using Metamorph software (Molecular Devices). For each location, multiplex imaging was performed by acquiring images corresponding to DAPI and protein staining using the same exposure time in subsaturation conditions. All quantitative image measurements were conducted with ImageJ. DAPI images were used to assess the number of cells per image. After background substraction, the average protein fluorescence intensity per cell was assessed by dividing the total intensity per image by the corresponding cell number and by averaging the values obtained in all locations. Nuclear counting of DAPI stainings were also used to assess the average cell number in the presence or absence of TGF-β1. Colocalization analysis of F-actin and α-SMA stainings was performed by using both the Manders coefficients and the colocalization highlighter plug-ins (ImageJ 1.41n).

qRT-PCR
-------

Cells were plated in triplicate, and the corresponding total RNA was isolated using the RNeasy Mini kit (QIAGEN). A total of 1 µg of RNA was reverse transcribed into cDNA using the High Capacity cDNA Reverse Transcription Kit and RNase inhibitor (Applied Biosystems). Real-time PCRs were performed on 40 ng of each cDNA sample using TaqMan Gene Expression Master Mix and TaqMan gene-specific primer pairs and probes for human genes encoding collagen type I, alpha 1 (*COL1A1*) (Hs00164004_m1), collagen type III, alpha 1 (*COL3A1*) (Hs00164103_m1), and the RNA polymerase II polypeptide A (*POLR2A*, used as a reference gene) (Hs00172187_m1), and for mouse genes encoding *Col1a1* (Mm00801666_g1), *Col3a1* (Mm01254476_m1), and *Polr2a* (Mm00839502_m1, used as a reference gene) (Applied Biosystems). Reactions were carried out for 40 cycles (95°C for 21 s and 60°C for 20 s) in a 7900HT Fast Real-Time PCR System (Applied Biosystems). Relative gene expression was assessed using the comparative Ct method as described elsewhere ([@B48]). In brief, a common threshold was defined in the exponential phase of the PCR amplification curves for each gene, and the corresponding threshold cycles (Ct) were obtained and averaged over each replicate. Relative gene expression with respect to *POLR2A* was assessed as *k*⋅2^--ΔCt^, where *k* is the ratio of the threshold numbers used for the target and the endogenous genes, respectively, and ΔCt is the difference between the average Ct of the target and the reference (endogenous) genes.

Sircol collagen assay
---------------------

Total secreted soluble collagen (types I--V) in the culture medium of fibroblasts was assessed using the Sircol collagen assay as reported elsewhere ([@B26]). Briefly, culture medium was collected for each experimental condition, concentrated, and stained with Sirius red dye to form a collagen-dye complex, which was precipitated and solubilized. The corresponding absorbance was measured at 540 nm with a microplate enzyme-linked immunosorbent assay (ELISA) reader, converted into collagen concentration through a calibrated standard curve, and multiplied by each sample volume to assess the total secreted collagen in micrograms. Results were normalized to total protein content, which was measured with the Lowry assay. Final results are shown as secreted collagen (micrograms)/total protein (micrograms).

Western blotting
----------------

Western blotting analysis of FAK activity was conducted as described elsewhere ([@B57]). In brief, fibroblasts were lysed in extraction buffer supplemented with phosphatase and protease inhibitors. Equal protein amounts were separated on 10% Mini-PROTEAN TGX precast gels (Bio-Rad), transferred to a polyvinylidene difluoride (PVDF) membrane (GE Healthcare), blocked, and incubated overnight with suitable primary antibodies including anti-FAK (3285; Cell Signalling), anti-FAK^pY397^ (700255; Invitrogen), anti--α-tubulin (5174 and 2144, Cell Signalling), or anti--β-actin (Sigma). The latter two markers were used as loading controls. Protein bands were labeled and visualized by chemiluminescence in a digital imaging system (ImageQuant LAS 4000; GE Healthcare). Protein band intensities were quantified with ImageJ and normalized to the corresponding loading control.

Single cell stiffness assessed from nanoindentation measurements with AFM
-------------------------------------------------------------------------

Cells were cultured on glass-bottomed 35-mm Petri dishes (MatTek) and placed on the stage of an inverted optical microscope (Olympus IX70-S8F2) equipped with a microinbucator (HCMIS ALA Science) to hold the temperature at 37°C. A commercial stand-alone AFM (Bioscope, Veeco) adapted to the optical microscope and provided with a low-spring constant (0.03 nN/nm) AFM cantilever (Veeco) was used to assess the Young's modulus (*E*) of single cells, following a protocol described in detail elsewhere ([@B3], [@B4]). The spring constant of the cantilever was calibrated using the thermal fluctuations method ([@B58]). In brief, three standard force versus displacement curves (*F* vs. *z*) were recorded on the perinuclear region of each cell at moderate loading force (∼1 nN) and low speed (∼5 µm/s). The *E* of a single cell was computed by fitting a suitable contact elastic model to each *F-*versus*-z* curve and averaging it over the three recordings. The final *E* for a cell population in each experimental condition was calculated from at least nine measurements for each independent experiment (*n* ≥ 2).

Statistical analysis
--------------------

Paired comparisons of data obtained from fibroblasts from the same patients were carried out using paired Student's *t* test. Comparisons between each different cell types and IPF fibroblasts, between selected EMT models (A549, H1975) and control fibroblasts, or between FAK^+/+^ and FAK^--/--^ fibroblasts were assessed by unpaired Student's *t* test. Statistical analyses were performed with either SigmaStat (Systat Software) or Graphpad Prism (Graphpad). Statistical significance was assumed at *p* \< 0.05. Unless otherwise stated, data are given as mean ± SE for all independent experiments (*n* ≥ 2).
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